5-Amino-1MQ Research Guide: NNMT Inhibition, Fat Metabolism & Preclinical Evidence

In the rapidly evolving landscape of metabolic research, few compounds have generated as much scientific interest as 5-Amino-1MQ (5-amino-1-methylquinolinium). While GLP-1 receptor agonists dominate mainstream headlines, researchers investigating the molecular underpinnings of obesity and metabolic dysfunction have increasingly turned their attention to a fundamentally different target: nicotinamide N-methyltransferase (NNMT). This enzyme, once considered a minor player in nicotinamide metabolism, has emerged as a critical regulator of fat cell biology, energy expenditure, and whole-body metabolic homeostasis.

5-Amino-1MQ represents the most well-characterized small-molecule NNMT inhibitor in current research, offering a mechanistically distinct approach to metabolic intervention that operates at the epigenetic and enzymatic level rather than through appetite suppression or receptor modulation. This comprehensive guide examines the science behind this compound, the preclinical evidence supporting its metabolic effects, and why researchers believe NNMT inhibition could represent a paradigm shift in how we understand and approach fat metabolism.

What Is 5-Amino-1MQ? A Primer on NNMT Inhibition

5-Amino-1MQ is a small-molecule, cell-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Structurally, it belongs to the methylquinolinium class of compounds, featuring a quinoline backbone with an amino group at the 5-position and a methyl group on the nitrogen atom. Its molecular formula is C??H??N??, with a molecular weight of approximately 159.21 g/mol.

Unlike peptide-based metabolic research compounds such as semaglutide or tirzepatide, which act on cell-surface receptors, 5-Amino-1MQ works intracellularly by directly binding to and inhibiting the NNMT enzyme. This intracellular mechanism gives it a fundamentally different pharmacological profile and set of downstream effects.

The compound was first characterized as an NNMT inhibitor in research published by Neelakantan et al. (2017), where it demonstrated potent inhibition of NNMT activity in both cell-free enzymatic assays and in adipocyte cell cultures. Since then, it has become the reference compound for NNMT inhibition research across multiple laboratories worldwide.

The NNMT Enzyme: Why It Matters for Fat Metabolism

To understand why 5-Amino-1MQ has attracted such intense research interest, you first need to understand the enzyme it targets. NNMT catalyzes the methylation of nicotinamide (vitamin B3) using S-adenosyl-L-methionine (SAM) as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH) as products.

For decades, this reaction was considered a simple clearance mechanism — a way for the body to dispose of excess nicotinamide. But research over the past 15 years has revealed that NNMT sits at a critical metabolic intersection, influencing at least four major pathways simultaneously:

1. NAD+ Biosynthesis

By methylating and thereby “consuming” nicotinamide, NNMT diverts this precursor away from the NAD+ salvage pathway. Nicotinamide is the primary substrate for nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ recycling. When NNMT activity is high, less nicotinamide is available for NAD+ production, effectively creating an “NAD+ drain.” This is why researchers investigating NAD+ supplementation strategies are increasingly interested in NNMT as a complementary target.

2. SAM/SAH Methylation Balance

NNMT consumes SAM (the universal methyl donor) and produces SAH (a methylation inhibitor). High NNMT activity therefore depletes the cell’s methylation capacity. Since histone methylation is a key epigenetic regulator of gene expression — including genes controlling adipogenesis, lipogenesis, and energy expenditure — NNMT activity can have profound effects on fat cell gene programs.

3. Adipose Tissue Biology

NNMT expression is markedly elevated in white adipose tissue (WAT) of obese individuals compared to lean controls. A landmark 2014 study by Kraus et al., published in Nature, demonstrated that NNMT expression in adipose tissue correlated positively with body mass index, insulin resistance, and adipocyte size. Crucially, the same study showed that antisense oligonucleotide (ASO) knockdown of NNMT in diet-induced obese mice reduced body weight and adiposity while improving insulin sensitivity — without changes in food intake.

4. Energy Expenditure Regulation

NNMT inhibition has been linked to increased polyamine flux, which in turn activates thermogenic gene programs in adipose tissue. The Kraus et al. study found that NNMT knockdown increased oxygen consumption and expression of uncoupling proteins, suggesting enhanced energy expenditure through futile cycling and thermogenesis.

“NNMT is a major regulator of adiposity and whole-body energy expenditure… NNMT inhibition in adipose tissue offers a novel approach to treat obesity and type 2 diabetes.” — Kraus et al., Nature, 2014 (PMID: 24670636)

Mechanism of Action: How 5-Amino-1MQ Blocks NNMT

5-Amino-1MQ functions as a substrate-competitive inhibitor of NNMT. Its quinolinium structure mimics the nicotinamide substrate, allowing it to bind within the enzyme’s active site and block the methylation reaction. However, unlike the natural substrate, 5-Amino-1MQ cannot be efficiently methylated by NNMT, so it occupies the binding pocket without being processed, effectively jamming the enzymatic machinery.

The inhibition mechanism proceeds through several well-characterized steps:

1. Active Site Binding: 5-Amino-1MQ enters the cell (it is membrane-permeable due to its small size and cationic charge) and competes with nicotinamide for binding to the NNMT active site.
2. Competitive Displacement: At sufficient concentrations, 5-Amino-1MQ outcompetes nicotinamide, reducing the rate of 1-MNA production.
3. NAD+ Salvage Restoration: With less nicotinamide being diverted to 1-MNA, more nicotinamide becomes available for NAMPT and the NAD+ salvage pathway, leading to increased intracellular NAD+ levels.
4. SAM Conservation: Reduced NNMT activity means less SAM is consumed, preserving the cell’s methylation potential and shifting the SAM/SAH ratio toward a more methylation-competent state.
5. Downstream Metabolic Effects: The combined increase in NAD+ availability and restored methylation balance triggers a cascade of metabolic changes, including altered histone methylation patterns, increased sirtuin activity (NAD+-dependent deacetylases), and activation of thermogenic and lipolytic gene programs.

Neelakantan et al. (2017) demonstrated that 5-Amino-1MQ inhibited NNMT with an IC?? in the low micromolar range in cell-free assays and produced significant reductions in lipid accumulation in 3T3-L1 adipocyte cultures at concentrations as low as 10 ?M (PMID: 28525751).

The NAD+ Connection: NNMT, Methylation, and Cellular Energy

One of the most compelling aspects of NNMT inhibition is its relationship to NAD+ biology. NAD+ (nicotinamide adenine dinucleotide) is arguably the most important coenzyme in cellular metabolism, serving as an essential cofactor for hundreds of enzymatic reactions including those in glycolysis, the TCA cycle, oxidative phosphorylation, and DNA repair.

NAD+ levels decline with age and in metabolic disease states, contributing to mitochondrial dysfunction, impaired DNA repair, and metabolic inflexibility. This decline has fueled enormous interest in NAD+ precursor supplementation — particularly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). However, precursor supplementation faces a fundamental limitation: if NNMT activity is elevated (as it is in obesity and aging), a significant portion of supplemented nicotinamide-based precursors may be diverted toward 1-MNA production rather than NAD+ synthesis.

This creates a compelling rationale for combining NNMT inhibition with NAD+ precursor strategies. By blocking the NNMT “drain,” 5-Amino-1MQ may help ensure that nicotinamide and its derivatives are channeled toward NAD+ production rather than being wastefully methylated. Several research groups have proposed this combination approach, though direct combination studies remain limited.

The relationship between NNMT, NAD+, and the sirtuins (particularly SIRT1 and SIRT3) is especially noteworthy. Sirtuins are NAD+-dependent deacetylases that regulate metabolic gene expression, mitochondrial biogenesis, and cellular stress responses. By increasing NAD+ availability, NNMT inhibition may indirectly enhance sirtuin activity, potentially amplifying the metabolic benefits through epigenetic reprogramming of fat cells.

Preclinical Fat Loss Research: What the Studies Show

The preclinical evidence for NNMT inhibition in fat metabolism is robust and comes from multiple independent research groups using different methodologies. Here are the key findings:

The Kraus et al. Nature Study (2014)

This foundational study used antisense oligonucleotides (ASOs) rather than 5-Amino-1MQ specifically, but established the proof of concept for NNMT inhibition in obesity. Key findings in diet-induced obese (DIO) mice:

• NNMT ASO treatment reduced body weight by approximately 6% over 4 weeks without affecting food intake
• White adipose tissue mass decreased significantly
• Insulin sensitivity improved (measured by glucose and insulin tolerance tests)
• Adipose tissue oxygen consumption increased, indicating enhanced energy expenditure
• Expression of thermogenic genes (UCP1, PGC-1?) increased in white adipose tissue
• Polyamine flux increased, suggesting a mechanistic link between NNMT inhibition and thermogenesis

Neelakantan et al. — 5-Amino-1MQ in Diet-Induced Obesity (2017)

This study directly evaluated 5-Amino-1MQ in a diet-induced obesity model and produced striking results (PMID: 28525751):

• DIO mice treated with 5-Amino-1MQ (20 mg/kg/day IP) for 11 days showed significant reductions in body weight
• Total fat mass decreased without changes in lean mass or food consumption
• Plasma total cholesterol levels decreased by approximately 30%
• Adipocyte size was significantly reduced in treated animals
• No observable toxicity or adverse effects during the treatment period
• The compound demonstrated selectivity for NNMT over other methyltransferases

Ruf et al. — Structural Biology of NNMT Inhibition (2018)

Researchers at the Structural Genomics Consortium solved the crystal structure of NNMT bound to various inhibitors, providing molecular-level insight into how compounds like 5-Amino-1MQ interact with the enzyme active site. This work has guided the development of next-generation NNMT inhibitors with improved potency and selectivity (PMID: 29800499).

Kannt et al. — NNMT in Human Adipose Tissue (2015)

This clinical correlation study examined NNMT expression in human adipose tissue biopsies from lean and obese subjects. NNMT mRNA and protein levels were significantly higher in subcutaneous and visceral adipose tissue from obese individuals compared to lean controls, and correlated with measures of insulin resistance. Weight loss through bariatric surgery reduced NNMT expression, further supporting the enzyme’s role in obesity pathophysiology (PMID: 25940003).

Adipocyte-Specific Effects: Shrinking Fat Cells at the Source

One of the most distinctive features of NNMT inhibition compared to other metabolic interventions is its direct action on adipocyte biology. While GLP-1 receptor agonists like semaglutide primarily reduce adiposity through appetite suppression and delayed gastric emptying, NNMT inhibitors appear to act directly on fat cells themselves.

In vitro studies using 3T3-L1 adipocytes (a standard cell culture model for fat cell biology) have demonstrated that 5-Amino-1MQ treatment produces several notable effects:

• Reduced lipid accumulation: Adipocytes treated with 5-Amino-1MQ during differentiation accumulate significantly less intracellular lipid, as measured by Oil Red O staining
• Decreased adipocyte size: Mature adipocytes exposed to 5-Amino-1MQ show reduced cell volume, suggesting enhanced lipolysis or reduced lipogenesis
• Altered gene expression: NNMT inhibition shifts the transcriptional program away from lipid storage genes and toward genes associated with energy expenditure and lipid oxidation
• Increased SAM levels: Intracellular SAM concentrations rise following NNMT inhibition, which in turn affects histone methylation patterns at key metabolic gene loci

These direct adipocyte effects are particularly interesting because they suggest that NNMT inhibition could potentially complement receptor-based approaches. A researcher studying metabolic pathways might explore whether combining an NNMT inhibitor with a GLP-1 agonist could produce additive or synergistic effects — reducing appetite centrally while simultaneously reprogramming fat cell metabolism peripherally.

5-Amino-1MQ and Metabolic Syndrome Markers

Beyond pure fat loss, NNMT inhibition has shown effects on multiple components of metabolic syndrome in preclinical models:

Cholesterol and Lipid Profiles

The Neelakantan et al. study reported approximately 30% reductions in plasma total cholesterol with 5-Amino-1MQ treatment. This is mechanistically plausible given NNMT’s role in methylation metabolism — the enzyme’s activity affects one-carbon metabolism, which intersects with lipid biosynthesis pathways. Additionally, increased NAD+ levels from NNMT inhibition could enhance SIRT1-mediated regulation of cholesterol metabolism genes like SREBP and LXR.

Insulin Sensitivity

Both the Kraus ASO study and subsequent pharmacological NNMT inhibition studies have shown improvements in glucose tolerance and insulin sensitivity. This effect likely reflects multiple mechanisms: reduced adipocyte size (smaller fat cells are more insulin-sensitive), decreased inflammatory adipokine secretion, improved mitochondrial function via enhanced NAD+ availability, and direct effects on insulin signaling pathways.

Inflammation

NNMT has been implicated in inflammatory signaling in adipose tissue macrophages and other immune cells. Elevated NNMT activity in obese adipose tissue correlates with increased expression of pro-inflammatory cytokines (TNF-?, IL-6, MCP-1). While direct anti-inflammatory effects of 5-Amino-1MQ require further characterization, the reduction in adipocyte hypertrophy alone would be expected to decrease adipose tissue inflammation through reduced mechanical stress and hypoxia signaling.

Hepatic Steatosis

Emerging evidence suggests NNMT plays a role in hepatic lipid metabolism as well. NNMT is expressed in the liver, and its inhibition has been associated with reduced hepatic triglyceride accumulation in some preclinical models. Given the strong association between NAFLD/NASH and metabolic syndrome, this represents an active area of investigation.

5-Amino-1MQ vs. GLP-1 Receptor Agonists: Different Mechanisms, Different Targets

With the enormous attention given to GLP-1 receptor agonists like semaglutide and retatrutide for metabolic research, it is important to understand how NNMT inhibition differs mechanistically:

The key differentiator is that 5-Amino-1MQ appears to produce fat loss without reducing food intake — a fundamentally different approach that preserves lean body mass while specifically targeting fat tissue metabolism. This has led researchers to hypothesize that NNMT inhibitors and GLP-1 agonists could potentially be complementary rather than competitive in research settings.

Comparison With Other Metabolic Research Compounds

Beyond GLP-1 agonists, 5-Amino-1MQ occupies a unique niche among metabolic research compounds. Here is how it compares to other commonly studied agents:

vs. AOD 9604

AOD 9604 is a modified fragment of human growth hormone (hGH fragment 176-191) studied for its lipolytic properties. While both compounds target fat metabolism, they work through entirely different pathways — AOD 9604 through growth hormone receptor signaling and beta-3 adrenergic pathways, while 5-Amino-1MQ through NNMT-mediated metabolic reprogramming. AOD 9604 research has shown stimulation of lipolysis without the diabetogenic effects of full-length hGH.

vs. MOTS-c

MOTS-c is a mitochondria-derived peptide that activates AMPK and has shown metabolic benefits in preclinical models. While both MOTS-c and 5-Amino-1MQ influence cellular energy metabolism, MOTS-c works as an exercise mimetic through AMPK activation, whereas 5-Amino-1MQ acts upstream by modulating NAD+ and methylation balance. Researchers interested in exercise mimetics may also want to explore SLU-PP-332, an ERR? agonist with potent exercise-mimetic properties.

vs. Tesamorelin

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog primarily studied for visceral adiposity reduction. It works through GH axis stimulation, which increases lipolysis and has demonstrated specific efficacy for reducing visceral (abdominal) fat in clinical trials. By contrast, 5-Amino-1MQ’s effects appear to be more broadly distributed across adipose depots.

vs. L-Carnitine

L-Carnitine facilitates fatty acid transport into mitochondria for beta-oxidation. It is a cofactor rather than an enzyme inhibitor, and its effects are limited by the rate of fatty acid mobilization and mitochondrial capacity. NNMT inhibition may complement carnitine by increasing mitochondrial biogenesis and NAD+ availability, potentially enhancing the cell’s capacity to oxidize the fatty acids that carnitine transports.

Dosing Protocols in Published Research

Understanding how 5-Amino-1MQ has been dosed in published research is essential for researchers designing their own studies. The following doses have been reported in the peer-reviewed literature:

In Vitro Studies

• 3T3-L1 adipocytes: 1–100 ?M concentration range, with significant effects observed at 10 ?M and above
• Treatment duration: Typically 24–72 hours for acute effects; full differentiation protocols (7–14 days) for adipogenesis studies
• Cell viability: No cytotoxicity reported at concentrations up to 100 ?M in most cell types tested

In Vivo Studies (Mouse Models)

• Dose: 20 mg/kg/day (intraperitoneal injection) in the Neelakantan et al. study
• Duration: 11 days in the primary efficacy study
• Model: C57BL/6 mice with diet-induced obesity (60% kcal from fat)
• Control: Vehicle-treated DIO mice on the same high-fat diet
• Outcomes measured: Body weight, body composition (MRI), food intake, plasma lipids, adipocyte histology

It is important to note that these doses were established in rodent models and cannot be directly extrapolated to other species. Allometric scaling, species-specific pharmacokinetics, and differences in NNMT expression patterns must all be considered when designing research protocols for other model organisms.

Safety Profile and Toxicology Data

The safety profile of 5-Amino-1MQ in preclinical models has been encouraging, though it must be emphasized that the compound remains in the research phase and comprehensive long-term toxicology studies have not been published:

Observed Safety Data

• Acute toxicity: No mortality or overt toxicity observed at 20 mg/kg/day IP for 11 days in mice
• Body weight: No abnormal weight loss beyond the targeted fat mass reduction
• Food intake: No anorexic effects — food consumption remained consistent between treated and control groups
• Lean body mass: Preserved during treatment, suggesting fat-specific effects
• Behavior: No reported changes in locomotor activity, grooming, or social behavior
• Selectivity: 5-Amino-1MQ has demonstrated selectivity for NNMT over other methyltransferases in enzymatic assays, though comprehensive off-target screening data is limited

Theoretical Concerns

• 1-MNA depletion: Since NNMT inhibition reduces 1-methylnicotinamide production, the consequences of chronically low 1-MNA levels require investigation. 1-MNA has been reported to have anti-inflammatory and anti-thrombotic properties in some studies, though its physiological significance remains debated.
• Methylation effects: Chronic NNMT inhibition would be expected to alter the SAM/SAH ratio, which could theoretically affect other methylation-dependent processes (DNA methylation, histone methylation, etc.). The tissue-specificity and magnitude of these effects under pharmacological NNMT inhibition require further study.
• Long-term metabolic effects: The consequences of sustained NNMT inhibition over months to years are unknown, as published studies have only examined short-term treatment periods.

Bioavailability and Pharmacokinetics

One of the practical advantages of 5-Amino-1MQ as a research tool is its favorable physicochemical properties. As a small molecule (MW ~159), it has inherent advantages over peptide-based compounds in terms of stability and potential routes of administration:

• Stability: The compound is chemically stable in aqueous solution and does not require the cold-chain storage typically needed for peptides
• Cell permeability: Despite carrying a positive charge (quaternary nitrogen), 5-Amino-1MQ demonstrates good cellular uptake, likely through organic cation transporters
• Oral bioavailability: While the published in vivo studies used intraperitoneal injection, the compound’s small size and water solubility suggest oral bioavailability may be feasible, though this has not been formally demonstrated in published peer-reviewed research
• Blood-brain barrier: Penetration across the BBB has not been extensively characterized. NNMT is expressed in the brain, so CNS effects remain an open question

Formal pharmacokinetic parameters (Cmax, Tmax, half-life, AUC, clearance, volume of distribution) have not been published for 5-Amino-1MQ in peer-reviewed literature as of early 2026. This represents an important gap in the research landscape that future studies will need to address.

Future Research Directions: Beyond Fat Loss

While the metabolic and anti-obesity effects of NNMT inhibition have received the most attention, emerging research suggests the enzyme may play important roles in several other biological contexts:

Cancer Biology

NNMT is overexpressed in numerous cancer types, including pancreatic, gastric, colorectal, renal, and bladder cancers. In tumor cells, elevated NNMT appears to promote metabolic reprogramming, epigenetic changes favoring proliferation, and resistance to certain chemotherapeutic agents. Several studies have demonstrated that NNMT knockdown or inhibition can reduce tumor cell proliferation and migration in vitro (PMID: 31127082). This has positioned NNMT inhibitors as potential tools for cancer metabolism research.

Aging and Longevity

Given NNMT’s role in NAD+ metabolism and the well-established connection between NAD+ decline and aging, NNMT inhibition is being explored in the context of geroscience. Age-related increases in NNMT expression could contribute to the NAD+ decline observed in aging tissues. By restoring NAD+ levels through NNMT inhibition rather than (or in addition to) precursor supplementation, researchers hope to address one of the root causes of metabolic aging.

Neurodegenerative Disease

NNMT expression is altered in neurodegenerative conditions including Parkinson’s disease and Alzheimer’s disease. In Parkinson’s disease, elevated NNMT in the brain has been hypothesized to contribute to dopaminergic neuron vulnerability through NAD+ depletion and the production of neurotoxic 1-MNA metabolites. The role of NNMT inhibition in neuroprotection is an emerging area of investigation (PMID: 23847049).

Fibrosis

Recent studies have identified NNMT as a regulator of fibrotic processes in multiple tissues. NNMT expression is upregulated in fibrotic liver, lung, and kidney tissue, and NNMT inhibition has shown anti-fibrotic effects in some preclinical models. The mechanism likely involves NNMT’s effects on TGF-? signaling and collagen gene expression through methylation-dependent epigenetic regulation.

Combination Approaches

Perhaps the most exciting frontier for 5-Amino-1MQ research is in combination with other metabolic compounds. Researchers have proposed investigating NNMT inhibition alongside:

• NAD+ precursors (NMN, NR): To maximize NAD+ production by blocking the NNMT drain while simultaneously supplying more precursor
• GLP-1 agonists: To combine central appetite suppression with peripheral fat cell reprogramming
• Exercise mimetics (SLU-PP-332, MOTS-c): To activate complementary energy expenditure pathways
• AMPK activators: To enhance the metabolic switch from anabolism to catabolism
• Sirtuin activators: Since NNMT inhibition increases NAD+ (the sirtuin cofactor), combination with direct sirtuin activators could produce synergistic effects on metabolic gene regulation

Frequently Asked Questions

References

1. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. PMID: 24670636
2. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PMID: 28525751
3. Kannt A, Pfenninger A, Teber L, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015;58(4):799-808. PMID: 25940003
4. Ruf S, Hallur MS, Engber TM, et al. Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase. Bioorg Med Chem Lett. 2018;28(5):922-925. PMID: 29800499
5. Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol. 2013;9(5):300-306. PMID: 23455543
6. Hong S, Moreno-Navarrete JM, Wei X, et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015;21(8):887-894. PMID: 26168293
7. Eckert MA, Coscia F, Chryplewicz A, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569(7758):723-728. PMID: 31127082
8. Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson’s disease. Neurosci Lett. 2003;342(1-2):13-16. PMID: 12727304
9. Neelakantan H, Wang HY, Vance V, et al. Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. J Med Chem. 2017;60(12):5015-5028. PMID: 28525751
10. Pissios P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends Endocrinol Metab. 2017;28(5):340-353. PMID: 28291578
11. Campagna R, Mateuszuk L, Wojnar-Lason K, et al. Nicotinamide N-methyltransferase in endothelium protects against oxidant stress-induced endothelial injury. Biochim Biophys Acta Mol Cell Res. 2021;1868(10):119082. PMID: 34146582
12. Brachs S, Polack J, Grötzinger C, et al. Genetic nicotinamide N-methyltransferase (Nnmt) deficiency in male mice improves insulin sensitivity in diet-induced obesity but does not affect glucose tolerance. Diabetes. 2019;68(3):527-542. PMID: 30523026

About Proxiva Labs: We supply premium research-grade compounds including 5-Amino-1MQ for qualified researchers. All products undergo rigorous third-party testing for purity and identity. Browse our full catalog of research peptides and compounds.